NAC Infusion Stopping Criteria
NAC infusion should be discontinued after completion of the standard 21-hour, 3-bag protocol (300 mg/kg total dose) in acute acetaminophen overdose patients who have normal liver function tests, undetectable acetaminophen levels, and no clinical evidence of hepatotoxicity. 1
Standard Protocol Completion
The FDA-approved regimen consists of three sequential doses administered over 21 hours total 1:
- Loading dose: 150 mg/kg over 1 hour
- Second dose: 50 mg/kg over 4 hours
- Third dose: 100 mg/kg over 16 hours
Criteria for Stopping After Standard Protocol
Stop NAC after 21 hours if ALL of the following are met 2:
- Acetaminophen level is undetectable or below treatment threshold
- AST and ALT remain normal (typically <50 IU/L)
- INR is normal
- Patient is asymptomatic with no signs of hepatotoxicity
- Patient can tolerate oral intake (if transition to oral NAC was being considered)
When to Continue Beyond 21 Hours
Continue NAC infusion beyond the standard protocol if ANY of the following exist 2:
- Elevated transaminases: AST or ALT >1,000 IU/L indicates severe hepatotoxicity requiring continued treatment 2
- Detectable acetaminophen levels: Persistent measurable acetaminophen suggests ongoing risk
- Coagulopathy: Elevated INR indicating hepatic synthetic dysfunction
- Clinical hepatotoxicity: Jaundice, encephalopathy, or other signs of liver failure 3
- Acute liver failure: Continue NAC regardless of time from ingestion, as it reduces mortality even in established liver failure 3
Special Circumstances Requiring Extended Treatment
Repeated Supratherapeutic Ingestion (RSI)
For patients with chronic acetaminophen ingestion at supratherapeutic doses 2:
- Continue NAC if AST 50-1,000 IU/L: 15% risk of progression to severe hepatotoxicity
- Continue NAC if AST >1,000 IU/L: High mortality risk (14% in studies)
- Contact poison control (1-800-222-1222) for specific guidance on duration 1
Hepatic Failure
Do not stop NAC in patients with established hepatic failure from acetaminophen 3:
- NAC reduces mortality by 28% absolute risk reduction in hepatic failure (80% vs 52%)
- Decreases cerebral edema and need for inotropic support
- Continue until clinical improvement or liver transplantation
Temporary Interruption vs. Complete Discontinuation
Severe Hypersensitivity Reactions
Temporarily stop the infusion for 1, 4:
- Severe hypersensitivity reactions (hypotension, wheezing, shortness of breath)
- Angioedema or significant respiratory symptoms
- Management: Administer diphenhydramine and symptomatic treatment
- Restart: May carefully restart 1 hour after antihistamine administration if symptoms resolve 4
Do NOT stop for minor reactions 4:
- Simple flushing requires no treatment; continue infusion
- Urticaria: treat with diphenhydramine but continue infusion
Permanently discontinue only if 1:
- Hypersensitivity reaction returns upon re-initiation
- Reaction increases in severity despite treatment
- History of previous severe hypersensitivity to NAC (contraindication)
Common Pitfalls to Avoid
- Do not stop prematurely in delayed presentations: Patients treated >10 hours post-ingestion have 26.4% risk of severe hepatotoxicity and require full protocol completion 2
- Do not rely solely on acetaminophen level: Check transaminases and INR before stopping, as hepatotoxicity can occur despite undetectable levels 2
- Do not stop for minor skin reactions: Flushing and mild urticaria occur in 30-60 minutes and typically resolve spontaneously without stopping infusion 1, 4
- Do not use Rumack-Matthew nomogram for RSI: The nomogram does not apply to repeated supratherapeutic ingestions 1
Monitoring Before Discontinuation
Obtain these labs before stopping NAC 2, 1:
- Acetaminophen level
- AST and ALT
- INR/PT
- Bilirubin
- Creatinine and BUN
- Electrolytes